Latest / Raleigh News Today | 2 Min News | The Daily News Now!
Gilead Surges on HIV and Cancer Wins | Raleigh News
Gilead Sciences just smashed Q2 expectations with strong performance across HIV, liver, and cancer drugs—boosting its full-year forecast and sending analysts bullish. The real star? Their HIV prevention shot Yeztugo, which boasts the highest patient retention in the PrEP market, helping propel the entire PrEP franchise past $1 billion quarterly in sales. Livdelzi for liver disease is gaining ground, and Trodelvy just got expanded approval for breast cancer, opening massive new markets. With key FDA decisions looming, Gilead’s multi-front execution is turning heads—and investors are taking…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.